TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
News Sep 16, 2009
“We’ve learned that no other suppliers have exactly our expertise in this area. We felt discontinuing this service left our customers with no viable option for highly modified radioactive oligonucleotides, and therefore we had to rescind our decision,” said TriLink CEO, Dr. Richard Hogrefe.
TriLink leads the industry in unique modified nucleic acids and mid-scale oligonucleotide synthesis. High quality products and technical support are its key strengths. TriLink operates a fully GMP laboratory with a QSR environment. TriLink has over 13 years experience synthesizing radiolabeled DNA and RNA oligonucleotides. 35S and 3H labeling of both phosphodiester and phosphorothioate oligonucleotides are offered, as well as additional modifications.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019